pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
CAR-T · news · pharmadog
← back to CAR-T
News · CAR-T
57
stories
2d
Exclusive: Third death revealed in China's popular but opaque trials
endpoints
3d
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
6d
After 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?
fiercebiotech
8d
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
8d
STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
stat
14d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
20d
Syphilis spreads while researchers contend with federal constraints and a drug shortage
stat
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
21d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
21d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
22d
J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech
endpoints
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
22d
Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy
biospace
24d
Legend Biotech CEO abruptly steps down without permanent replacement
fiercebiotech
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
27d
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
28d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
Jul 17, 26
India’s life sciences sector at turning point for innovation: Report
biospace
Jul 16, 26
‘Substantially better than before’: Why India has golden opportunity to build on innovative R&D wins
fiercebiotech
Jul 8, 26
Bryan Johnson’s chronic disease is notoriously difficult to diagnose
stat
Jul 8, 26
Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
stat
Jun 7, 26
STAT+: Competition for obesity drugs, clinical blind spots, and more news from ADA
stat
Jun 6, 26
STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet ending
stat
Jun 3, 26
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
biopharma dive
Jun 3, 26
STAT+: Legend Biotech emerged as a rare market winner
stat
Jun 3, 26
Lilly, Ascidian link up in RNA exon editing pact
biopharma dive
Jun 2, 26
Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
endpoints
← prev
page 1 of 2
next →
